Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States.
Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27695, United States.
J Med Chem. 2022 Dec 22;65(24):16338-16352. doi: 10.1021/acs.jmedchem.2c01141. Epub 2022 Nov 30.
MicroRNAs (miRNAs) are noncoding RNA molecules of 22-24 nucleotides that are estimated to regulate thousands of genes in humans, and their dysregulation has been implicated in many diseases. MicroRNA-122 (miR-122) is the most abundant miRNA in the liver and has been linked to the development of hepatocellular carcinoma and hepatitis C virus (HCV) infection. Its role in these diseases renders miR-122 a potential target for small-molecule therapeutics. Here, we report the discovery of a new sulfonamide class of small-molecule miR-122 inhibitors from a high-throughput screen using a luciferase-based reporter assay. Structure-activity relationship (SAR) studies and secondary assays led to the development of potent and selective miR-122 inhibitors. Preliminary mechanism-of-action studies suggest a role in the promoter-specific transcriptional inhibition of miR-122 expression through direct binding to the liver-enriched transcription factor hepatocyte nuclear factor 4α. Importantly, the developed inhibitors significantly reduce HCV replication in human liver cells.
MicroRNAs (miRNAs) 是 22-24 个核苷酸的非编码 RNA 分子,据估计可以调节人类数千个基因,其失调与许多疾病有关。miR-122 是肝脏中最丰富的 miRNA,与肝细胞癌和丙型肝炎病毒 (HCV) 感染的发展有关。它在这些疾病中的作用使 miR-122 成为小分子治疗的潜在靶标。在这里,我们报告了一种新的磺酰胺类小分子 miR-122 抑制剂的发现,该抑制剂是通过基于荧光素酶的报告基因检测的高通量筛选发现的。结构-活性关系 (SAR) 研究和二级测定导致了强效和选择性的 miR-122 抑制剂的发展。初步的作用机制研究表明,通过直接结合富含肝的转录因子肝细胞核因子 4α,在 miR-122 表达的启动子特异性转录抑制中发挥作用。重要的是,所开发的抑制剂可显著降低人肝细胞中的 HCV 复制。